• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

175.41 -3.35 (-1.87%)
Official Closing Price Updated: 7:00 PM EST, Nov 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,581,073
Open 177.10
Bid (Size) 165.50 (100)
Ask (Size) 188.00 (400)
Prev. Close 178.76
Today's Range 174.03 - 178.29
52wk Range 153.41 - 212.71
Shares Outstanding N/A
Dividend Yield 0.53%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers
November 19, 2026
From AstraZeneca
Via Business Wire
AstraZeneca PLC (NYSE:AZN) as a GARP Case Study: Growth at a Reasonable Price ↗
November 19, 2026
Via Chartmill

Performance

52-Week Range 17.5% below 52-week high
175.41
153.4152W Low 212.7152W High
1 Week 6.5% below 1-week high
174.031W Low 187.691W High

AstraZeneca PLC - American Depositary Shares (AZN) traded between $153.41 and $212.71 over the past 52 weeks and last traded at $175.41, 17.5% below its 52-week high. Over the past week it ranged between $174.03 and $187.69.

Past 12 Months
-4.9%
+3.9%
+6.6%
-7.6%
-6.9%
-6.9%
1W -$9.04
1M +$6.59
3M +$10.92
6M -$14.34
YTD -$13.00
1Y -$13.00

AZN was -6.9% over the past year, -7.6% over six months, -6.9% year to date, -4.9% in the last week.

12 Months vs Market
AZN
-6.9%
DIA
+6.3%
SPY
+8.0%
QQQ
+7.5%
IWM
+13.2%

Over the past 12 months AZN returned -6.9% versus DIA (Dow) +6.3%, SPY (S&P 500) +8.0%, QQQ (Nasdaq 100) +7.5% and IWM (Russell 2000) +13.2%.

Volume & Liquidity 0.86× 3-mo avg
Today 2,581,073 3-mo avg 3.0M
1W
2.3M
1M
3.0M
3M
3.0M
6M
3.0M
YTD
2.6M
1Y
2.6M

AZN most recently traded 2,581,073 shares against a 3-month average daily volume of 3.0M.

More News

Read More
News headline image
Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
November 13, 2026
From AstraZeneca
Via Business Wire
News headline image
Where Will IonQ Stock Be in 5 Years? ↗
November 12, 2026
Via The Motley Fool
AstraZeneca (NYSE:AZN) Stands Out for Dividend Quality and Sustainable Payout ↗
November 05, 2026
Via Chartmill
News headline image
AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
November 10, 2026
From AstraZeneca
Via Business Wire
News headline image
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
November 09, 2026
From Gabelli Funds
Via GlobeNewswire
News headline image
AstraZeneca: 3 Key Takeaways for Long-Term Investors ↗
November 01, 2026
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
AstraZeneca (AZN) Q3 2026 Earnings Call Transcript ↗
October 31, 2026
Via The Motley Fool
Topics Earnings
News headline image
AstraZeneca Q3 Earnings Call Highlights ↗
October 30, 2026
Via MarketBeat
Topics ETFs Earnings
News headline image
AstraZeneca results: 9M and Q3 2026
October 30, 2026
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing
October 28, 2026
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update ↗
October 26, 2026
Via MarketBeat
Topics ETFs
News headline image
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
October 25, 2026
From AstraZeneca
Via Business Wire
News headline image
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
October 25, 2026
From AstraZeneca
Via Business Wire
News headline image
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
October 24, 2026
From AstraZeneca
Via Business Wire
News headline image
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
October 24, 2026
From AstraZeneca
Via Business Wire
News headline image
ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
October 22, 2026
From AstraZeneca
Via Business Wire
News headline image
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗
October 21, 2026
Via The Motley Fool
News headline image
TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week
October 20, 2026
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib
October 19, 2026
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint ↗
October 12, 2026
Via MarketBeat
Topics ETFs
News headline image
Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗
October 10, 2026
Via The Motley Fool
News headline image
2 Growth Stocks to Buy in October ↗
October 08, 2026
Via The Motley Fool
News headline image
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
October 05, 2026
From AstraZeneca
Via Business Wire

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the New York Stock Exchange
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the New York Stock Exchange
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 175.41
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 11/19/26 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap